Shafique Virani - Dec 15, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Business Officer
Signature: /s/ Jonathan Golightly, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Dec 15, 2023
Transactions value $: -$132,840
Form type: 4
Date filed: 12/19/2023, 07:22 PM
Previous filing: Nov 17, 2023
Next filing: Jan 18, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Options Exercise	$40K	+18K	+13.16%	$2.22	155K	Dec 15, 2023	Direct	F1
transaction	RXRX	Class A Common Stock	Sale	-$173K	-18K	-11.63%	$9.60	137K	Dec 15, 2023	Direct	F1

Showing 1 to 2 of 2 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Options Exercise	$0	-18K	-4.53%	$0.00	379K	Dec 15, 2023	Class A Common Stock	18K	$2.22	Direct	F1, F3
holding	RXRX	Stock Option (Right to Buy)						213K	Dec 15, 2023	Class A Common Stock	0	$8.55	Direct	F2
holding	RXRX	Stock Option (Right to Buy)						80.5K	Dec 15, 2023	Class A Common Stock	0	$11.40	Direct	F4
holding	RXRX	Stock Option (Right to Buy)						5.44K	Dec 15, 2023	Class A Common Stock	0	$11.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
F2	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F3	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F4	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.